

**The Journal of Obstetrics and Gynecology of India**  
**Comparison of Effectiveness of Different Protocols used for Controlled Ovarian  
Hyperstimulation in Intra-Uterine Insemination Cycle**  
--Manuscript Draft--

<b>Manuscript Number:</b>	JOGI-D-17-00324
<b>Full Title:</b>	Comparison of Effectiveness of Different Protocols used for Controlled Ovarian Hyperstimulation in Intra-Uterine Insemination Cycle
<b>Article Type:</b>	Original Article
<b>Corresponding Author:</b>	Azadeh Patel Nova IVI fertility clinic INDIA
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	Nova IVI fertility clinic
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Azadeh Patel
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Azadeh Patel Manish Banker Ashwini Deshmukh Sandeep Shah
<b>Order of Authors Secondary Information:</b>	
<b>Funding Information:</b>	
<b>Abstract:</b>	<p><b>Introduction:</b> Intra-uterine insemination (IUI) is one of the most commonly performed procedure of assisted reproductive technologies (ART), for the treatment of infertility. Controlled ovarian hyperstimulation (COH) is an important first step while performing IUI. This study aims at establishing a relationship between stimulation protocol and pregnancy outcome following IUI.</p> <p><b>Methods:</b> This is a retrospective study of 1001 cycles of IUI in which the patients were divided into two groups: Group A (CC only) and Group B (CC+ GN or GN alone). The primary outcome assessed was Clinical Pregnancy Rates (CPR) and the secondary outcomes were Miscarriage Rate (MR), Multiple Pregnancy Rates (MPR), Follicle Numbers and Endometrial Thickness (ET).</p> <p><b>Results:</b> Significantly, higher CPR was observed in Group B in comparison to Group A (14.55% v/s 7.82%; p = 0.05). MR was much higher in Group A in comparison to Group B, (14.29% v/s 4.65%; p = 0.94), but it was non- significant. The Follicle Number and the Endometrial Thickness of the Group A v/s Group B are (1.54 ± 0.69 v/s 1.90 ± 1.04; p = 0.0003) and (8.56 ± 1.33 v/s 8.39 ± 1.29; p = 0.1784), respectively and for subgroups, Group B1 and Group B2 are 1.92 ± 0.99 v/s 1.65 ± 0.92; p = 0.0008 and 8.32 ± 1.27 v/s 8.69 ± 1.24; p = 0.0004), respectively.</p> <p><b>Conclusion:</b> GN, either alone or the combination with CC, gives a higher CPR and a lower abortion rate following IUI, however, increasing the Multiple Pregnancy Rate.</p>

**Title:** Comparison of Effectiveness of Different Protocols used for Controlled Ovarian Hyperstimulation in Intra-Uterine Insemination Cycle

**Short Title:** Effects of Controlled Ovarian Hyperstimulation on Intrauterine Insemination Result

**Authors:** Banker Manish<sup>1</sup>, Patel Azadeh<sup>2</sup>, Deshmukh Ashwini<sup>3</sup>, Shah Sandeep<sup>4</sup>

**Affiliations:**

<sup>1</sup>Director, Nova IVI Fertility Clinic, Ahmedabad, India. E-mail: [manish.banker@novaivifertility.com](mailto:manish.banker@novaivifertility.com)

<sup>2</sup>Associate consultant, Nova IVI Fertility Clinic, Ahmedabad, India. E-mail: [azadeh.patel@novaivifertility.net](mailto:azadeh.patel@novaivifertility.net)

<sup>3</sup>Former Fellow, Nova IVI Fertility Clinic, Ahmedabad, India. E-mail: [ashvini.deshmukh@novaivifertility.net](mailto:ashvini.deshmukh@novaivifertility.net)

<sup>4</sup>Senior consultant, Nova IVI Fertility Clinic, Ahmedabad, India. E-mail: [sandeep.shah@novaivifertility.net](mailto:sandeep.shah@novaivifertility.net)

**Corresponding Author:** Patel Azadeh

**Address:** Nova IVI Fertility Clinic, 108, Swastik Society, Behind St. Xavier's Ladies Hostel, Navrangpura, Ahmedabad, India-380009

**E-mail:** [azadeh.patel@novaivifertility.net](mailto:azadeh.patel@novaivifertility.net)

**Phone:** +91-9723819511

**Fax:** +91-79-264226216

**Author Description:**



Dr. Manish Banker is Executive Director, Nova IVI Fertility, Nova Pulse IVF Clinics Pvt. Ltd., Bangalore. He has passed MBBS in 1984 and MD in 1987, from Gujarat University with Gold Medal. He holds a Diploma in Endoscopy (1987) from University of Kiel, Germany. Dr. Banker is a representative, Chairman and member of various National and International Medical centers and Committees. He has also bagged many prestigious awards and recognitions in his long career. He has many journal articles, text book chapters and posters under his name and also participated in clinical trials. Dr. Banker also presented as orator at

various events. He has also undergone some trainings Fellowship program in Reproductive Medicine, NIF Fellowship program and FOGSI recognized Courses.

**Ethical statement:**

The authors declare that there is no conflict of interest regarding the publication of this paper.

1  
2  
3  
4 **Title:** Comparison of Effectiveness of Different Protocols used for Controlled Ovarian Hyperstimulation in Intra-  
5  
6 Uterine Insemination Cycle

7  
8 **Abstract**

9  
10 **Introduction:** Intra-uterine insemination (IUI) is one of the most commonly performed procedure of assisted  
11  
12 reproductive technologies (ART), for the treatment of infertility. Controlled ovarian hyperstimulation (COH) is an  
13  
14 important first step while performing IUI. This study aims at establishing a relationship between stimulation protocol  
15  
16 and pregnancy outcome following IUI.

17  
18 **Methods:** This is a retrospective study of 1001 cycles of IUI in which the patients were divided into two groups:  
19  
20 Group A (CC only) and Group B (CC+ GN or GN alone). The primary outcome assessed was Clinical Pregnancy  
21  
22 Rates (CPR) and the secondary outcomes were Miscarriage Rate (MR), Multiple Pregnancy Rates (MPR), Follicle  
23  
24 Numbers and Endometrial Thickness (ET).

25  
26 **Results:** Significantly, higher CPR was observed in Group B in comparison to Group A (14.55% v/s 7.82%;  $p =$   
27  
28 0.05). MR was much higher in Group A in comparison to Group B, (14.29% v/s 5.43%;  $p = 0.94$ ), but it was non-  
29  
30 significant. The Follicle Number and the Endometrial Thickness of the Group A v/s Group B are  $(1.54 \pm 0.69$  v/s  $1.90$   
31  
32  $\pm 1.04$ ;  $p = 0.0003$ ) and  $(8.56 \pm 1.33$  v/s  $8.39 \pm 1.29$ ;  $p = 0.1784$ ), respectively and for subgroups, Group B1 and  
33  
34 Group B2 are  $1.92 \pm 0.99$  v/s  $1.65 \pm 0.92$ ;  $p = 0.0008$  and  $8.32 \pm 1.27$  v/s  $8.69 \pm 1.24$ ;  $p = 0.0004$ ), respectively.

35  
36  
37 **Conclusion:** GN, either alone or the combination with CC, gives a higher CPR and a lower abortion rate following  
38  
39 IUI, however, increasing the Multiple Pregnancy Rate.

40  
41 **Keywords:** Infertility, Intrauterine Insemination, Clomiphene Citrate, Gonadotropins, Controlled Ovarian  
42  
43 Hyperstimulation  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 **Introduction**  
5  
6

7 Infertility, a worldwide health issue is the inability of a couple to conceive, despite unprotected intercourse for the  
8 period of one year. Most common causes for infertility include mild endometriosis, male factor, unexplained  
9 infertility, ovulatory dysfunction, and aging (1, 2). Intrauterine insemination (IUI) is the most performed treatment in  
10 women with infertility owing to mild male factor infertility, anovulation, endometriosis with at least one patent tube,  
11 and unexplained infertility (3, 4, 5).  
12  
13  
14

15 Simplicity, easy management, low cost, and absence of potentially serious complications make IUI a leading  
16 routinely used technique for infertility (3, 6, 7). Further, development in the type of stimulation protocols,  
17 gonadotropins, ultrasound monitoring and sperm preparation techniques has enhanced the success rate of IUI.  
18  
19  
20  
21

22 IUI may be performed in natural cycle as well as in combination with controlled ovarian hyperstimulation (COH)  
23 (6). A higher CPR was observed in the latter cases in some studies (8), thus leading to using potential ovarian  
24 stimulants such as clomiphene citrate (CC). Higher pregnancy rates are observed in patients who were given CC (5,  
25 9). Bae and co-workers observed a higher rate of pregnancy in patients administered with 3-days treatment of CC  
26 than those given 5-day treatment with CC. This was believed to be due to an adequate endometrial growth by CC in  
27 the 3-Day treatment (9). Gonadotropins (GN) such as human menopausal gonadotropin (hMG), follicle stimulating  
28 hormone (FSH) have also been used as an alternative source for COH (6, 10, 11, 12). GNs although more responsive  
29 in COH than CC, are expensive and have certain associated AEs [Ovarian Hyperstimulation Syndrome (OHSS), and  
30 high-order multiple pregnancies]. But, being highly responsive and effective these are used in COH (5). Using a  
31 combination of CC and GN; COH and IUI can be made a cost effective and efficient process.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 In this study, we assessed the efficacy and safety of CC, GN alone and in combination with CC for COH in infertile  
44 female patients undergoing IUI. The study aimed at establishing a standard ovulation stimulation protocol including  
45 the type and dose of the ovarian stimulants (including CC and GNs *etc.*) to be used combined with IUI to treat  
46 infertility.  
47  
48  
49  
50

51 **Materials and Methods**  
52

53 This was a retrospective, observational study conducted from 1 November, 2014 to 29 February, 2016 under good  
54 clinical practices as per the International Conference on Harmonization (ICMR, 2006) guidelines and the Declaration  
55 of Helsinki (13). Women unable to conceive due to ovulatory dysfunction, mild male factors, unexplained infertility,  
56 mild endometriosis, *etc.* were included in the study. Following the physical examination and medical history  
57  
58  
59  
60  
61

1  
2  
3  
4 collection, baseline scan for the female patients (willing to participate) was performed on Day 2 or Day 3. The  
5  
6 patients were divided into two groups: Group A received CC and Group B received GN [Human Menopausal  
7  
8 Gonadotropin (hMG)]. The patients in Group B were subdivided into two subgroups: Group B1 received GNs (hMG)  
9  
10 plus CC and Group B2 received GN only. **Figure 1** represents the patient disposition. The dosage details are given in  
11  
12 **Figure 2.**

13  
14 Post semen collection by masturbation and liquefaction (at room temperature), it was analysed for pre wash count  
15  
16 and motility under microscope. The concentrate of motile sperms was obtained using either swim up or density  
17  
18 gradient technique and was re-analysed for post wash count. A final volume of 0.5 ml was used for insemination.

19  
20 IUI was performed 38 hours after the administration of Injection hCG (Injection Ovitrelle® 250 microgram, Merck  
21  
22 Sereno) using the treated semen samples. Urine pregnancy test was performed to confirm the positive pregnancy if  
23  
24 the patients did not have their periods within two weeks and if positive, sonography was performed one week later.  
25  
26 The CPR was the primary outcome, while miscarriage rate (MR), multiple pregnancy rate (MPR), endometrial  
27  
28 thickness and follicle number were the secondary outcomes. These were compared among different patient groups  
29  
30 using SPSS version 19.0 (IBM Corporation, United States).  
31

## 32 33 **Results**

34  
35 A total of 1001 patients were distributed into three different groups depending on the type of the treatment given.  
36  
37 **Table 1** gives the number of patients with different etiologies for infertility among the two patient groups; which was  
38  
39 found to be non-significant ( $p = 0.1161$ ).

40  
41 CPR varied significantly between Group A (n=9) and Group B (n=129). It was higher in Group A v/s Group B  
42  
43 (7.82% v/s 14.55 %); ( $p = 0.05$ ). The subgroup analysis of Group B1 (n=101) and Group B2 (n=28) showed  
44  
45 comparable CPR *i.e.* (14.44% v/s 14.97%, respectively); ( $p = 0.85$ ) (**Table 2**).

46  
47 MR was higher in Group A patients (n=1) in comparison to Group B (n=7) (14.29% v/s 5.43%;  $p = 0.94$ ); but the  
48  
49 difference was not significant. The test of significance could not be performed in the groups B1 (6/129, 4.65%) and  
50  
51 B2 (1/129, 0.077%) due to a small sample size.

52  
53 While no multiple pregnancies were observed in Group A, the MPR was 13.17 % in Group B. Among a total 17  
54  
55 patients exhibiting multiple pregnancy; 11 and 6 patients belonged to Group B1 and B2, respectively, which was  
56  
57 non-significant (10.89% v/s 21.42%;  $p = 0.14$ ). Thus, MPR was higher in patients receiving GN alone.  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Group A had a lower number of follicles than Group B ( $1.54 \pm 0.69$  v/s  $1.90 \pm 1.04$ ;  $p = 0.0003$ ) which was found to  
5  
6 be statistically significant, while Group B1 had a higher number of follicles than Group B2 ( $1.92 \pm 0.99$  v/s  $1.65 \pm$   
7  
8  $0.92$ ;  $p = 0.0008$ ). The difference in endometrial thickness was non-significant between groups (Group A:  $8.56 \pm$   
9  
10  $1.33$  v/s Group B:  $8.39 \pm 1.29$ ;  $p = 0.17$ ). The comparison between the subgroups, showed that the follicle number  
11  
12 ( $1.92 \pm 0.99$  v/s  $1.65 \pm 0.92$ ;  $p = 0.0008$ ) was significantly higher in Group B1 than in Group B2, respectively.  
13  
14 While, endometrial thickness ( $8.32 \pm 1.27$  v/s  $8.69 \pm 1.24$ ;  $p = 0.0004$ ) was significantly higher in Group B2  
15  
16 **(Table3).**  
17

### 18 **Discussion**

19  
20 The effectiveness of different protocols for COH that can be used in combination with IUI was assessed in the  
21  
22 current study in terms of primary (CPR) and secondary outcomes (MR, MPR, Follicle Numbers, Endometrial  
23  
24 Thickness).  
25

26 In the present study, CPR was significantly higher in Group B patients who received GN alone or in combination  
27  
28 with CC, in comparison to Group A patients, *i.e.*, 14.55 % and 7.82% ( $p = 0.05$ ) who received CC alone. CPR was  
29  
30 comparable between the groups (Group B1 v/s Group B2) receiving GN+CC or GN alone (14.44% v/s 14.97%;  $p =$   
31  
32  $0.86$ ).  
33

34 Previous studies have reported varying outcomes on following use of CC and hMG alone and in combination.  
35  
36 Deshpande *et al* (2013) reported 13.89%, 15.58% and 7.43% CPR, in patient groups treated with hMG + CC, hMG  
37  
38 only and CC only, respectively (7). The pregnancy rate was higher when low dose of hMG (75 IU) was administered  
39  
40 either alone or in combination with CC (15.58% and 13.89%, respectively). Similar conclusion was drawn by  
41  
42 Kamath *et al* (2010) (10).  
43

44 The per cycle pregnancy rates for CC+IUI, FSH+IUI and IVF were 7.6%, 9.8% and 30.7%, respectively, obtained  
45  
46 during FASTT (The Fasttrack And Standard Treatment Trial) study (14). Recently, Karadag *et al* (2016) observed a  
47  
48 higher CPR in the GN group than in the CC group (15). The higher pregnancy rates after using GN could be due to a  
49  
50 better follicular development, development of multiple follicles and good endometrial thickness.  
51

52 Recently, in a study conducted by Diamond *et al* (2015) in women with unexplained infertility aged 18-40 years, the  
53  
54 CPRs in the patient groups given GN alone v/s CC alone were 35.5% v/s 28.3%, respectively. The multiple gestation  
55  
56 rates were higher in GN only group (31.8%;  $p = 0.006$ ) than that in CC only group (9%;  $p = 0.44$ ). Mostly, twins (4,  
57  
58 1.3%) were found to be born in CC only group, while there were 25 twins (8.3%) and 6 (2%) triplets in GN only  
59  
60

1  
2  
3  
4 treatment group (16). This could possibly be due to multiple follicular development and multiple ovulation. The  
5  
6 present study also have demonstrated multiple follicles with the use of GNs.

7  
8 Mukherjee and coworkers conducted a prospective, randomized study comparing the effect of the single dose of  
9  
10 uFSH + CC with only CC. The CPR observed was 17% v/s 8.3% ( $p = 0.0001$ ) in patient groups administered with a  
11  
12 combination of uFSH + CC v/s CC only, respectively. The difference in MR was observed ( $p = 0.99$ ). MR was  
13  
14 higher in Group A patients ( $n=1$ ; 14.29%) than Group B ( $n= 7/129$ ; 5.43%); but the difference was not significant ( $p$   
15  
16 = 0.94). The test of significance could not be performed in the groups B1 (6/129; 4.65%) and B2 (1/129; 0.077%)  
17  
18 due to a small sample size. Higher MR in CC group can be due to inappropriate Endometrial Thickness due to its  
19  
20 anti-oestrogenic nature.

21  
22 In an open labelled, randomized study by Peerear *et al* (2015), CPR in hMG only v/s CC only patient groups were  
23  
24 14.4% (48/334)v/s 9% (29/323).The same study reported 8.5 mm v/s 7.5 mm endometrial thickness in hMGv/s CC  
25  
26 patients groups, respectively ( $p < 0.001$ ).The CPR and Endometrial Thickness in our study were 14.97% v/s 7.82%  
27  
28 and  $8.69 \pm 1.24$  mm v/s  $8.56 \pm 1.33$  mm in the GN (hMG) only (Group B2)v/s CC (Group A) only groups,  
29  
30 respectively. Thus, the results were in agreement with the study by Peerear and coworkers.

31  
32 Denkart and coworkers compared the CPR, MPR and live births in patient groups (with unexplained infertility and  
33  
34 male subfertility) given CConly and FSH only. The respective outcome rates were 38% and 34.3%, 7.4% and 4.3%  
35  
36 and 70.4% and 73.9%, in CC only and FSH only groups, respectively(17). The dose given in the current study was  
37  
38 almost same, for all the treatment groups, as in the above two studies, *viz.*, GN alone group was given 75 IU daily  
39  
40 from Day 2/3 of natural cycle; CC+GN group was administered with 50 mg CC from Day 2- Day 6 and 75 IU GN on  
41  
42 alternate days as Day 3, Day 5 and Day 7. The comparable rates for the outcomes assessed were observed in the  
43  
44 above two studies and the present study.

45  
46 Karadag *et al* observed no multiple pregnancies in both the patient groups (15). However, in the present study, no  
47  
48 cases of multiple pregnancies were observed in CC alone patient group, while a higher rate was seen in hMG alone  
49  
50 group (21.42%) than in CC+hMG group (10.89%).

51  
52 However, in a study by Abdelazim and co-workers showed contrasting results to the present study wherein CPR was  
53  
54 higher in CC+hMG v/s hMG only group; 26.7% v/s 6.7%, respectively. Although, no significant differences were  
55  
56 found in the outcomes such as endometrial thickness and number of follicles (18). Whereas, in the present study  
57  
58 significant differences were observed in the endometrial thickness ( $8.35 \pm 1.44$  mm v/s  $8.63 \pm 1.43$  mm in  
59  
60



1  
2  
3  
4 CC+hMGv/shMG only group, respectively) and number of follicles ( $2.01\pm0.99$  v/s  $1.69\pm0.94$  in CC+hMGv/shMG  
5  
6 only group, respectively) for the concerned groups.

7  
8 Thus, based on the findings of present study and the past research, we could state that the protocol followed in our  
9  
10 study could be used as an effective, standard protocol for COH with IUI. The stepwise protocol given in **Figure 2**  
11  
12 should be followed.  
13

### 14 **Conclusion**

15  
16 GN, either alone or in combination with CC, gives a higher CPR and a lower MR following IUI, however, increasing  
17  
18 the MPR. Thus, GN or the combination of GN and CC can be used for an effective COH in combination with IUI for  
19  
20 improved CPRs.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## References

- (1) Kumar S, Mohsen N, Malini S. Association of Obesity with Male Infertility among Infertile Couples is not Significant in Mysore, South India. *Adv Stud Biol* 2013;5: 319-325.
- (2) Shadap A. Causes of Infertility among Married Women-A Review.
- (3) Soria M, Pradillo G, García J, Ramón P, Castillo A, Jordana C, Paricio P. Pregnancy predictors after intrauterine insemination: analysis of 3012 cycles in 1201 couples. *J Reprod Infertil* 2012;13: 158-166.
- (4) Merviel P, Heraud MH, Grenier N, Lourdel E, Sanguinet P, Copin H. Predictive factors for pregnancy after intrauterine insemination (IUI): an analysis of 1038 cycles and a review of the literature. *Fertil Steril* 2010;93: 79-88.
- (5) Chaudhary K, Suri V, Dhaliwal LK, Gainer S. Comparison of the efficacy of letrozole and low-dose gonadotropin combination with clomiphene and low-dose gonadotropin combination as a controlled ovarian stimulation regime prior to intrauterine insemination in patients with unexplained infertility. *Fertility Science and Research* 2014;1: 98.
- (6) Koli P, Anil M, Ramya N, Patil K, Swamy M. Intrauterine insemination: a retrospective review on determinants of success. *Int J Reprod Contracept Obstet Gynecol* 2013;2: 311-314.
- (7) Deshpande SA, Deshpande AB. Intra uterine insemination an experience in rural population. *IJMRHS* 2013;2: 341-349.
- (8) Liu J, Chian R, Ma X, Wang W, Cui Y. The Pregnancy Outcomes Comparison on Natural or Controlled Ovarian Stimulation Cycles in Intrauterine Insemination Treatment: An Analysis of 8,893 Cycles. *La Prensa Medica* 2016;2016:
- (9) Bae S-A, Joo J-K, Choi J-R, Kim S-S, Lee K-S. Clinical outcomes of three-or five-day treatment with clomiphene citrate combined with gonadotropins and a timed intercourse cycle in polycystic ovary syndrome patients. *CERM* 2015;42: 106-110.
- (10) Kamath MS, Bhave P, Aleyamma T, Nair R, Chandy A, Mangalaraj AM, Muthukumar K, George K. Predictive factors for pregnancy after intrauterine insemination: A prospective study of factors affecting outcome. *J Hum Reprod Sci* 2010;3: 129.

- 1  
2  
3  
4 (11) Kaser DJ, Goldman MB, Fung JL, Alper MM, Reindollar RH. When is clomiphene or gonadotropin  
5  
6 intrauterine insemination futile? Results of the Fast Track and Standard Treatment Trial and the Forty and  
7  
8 Over Treatment Trial, two prospective randomized controlled trials. *Fertil Steril* 2014;102: 1331-1337. e1331.  
9  
10 (12) Rashidi BH, Tanha FD, Rahmanpour H, Ghazizadeh M. Luteal phase support in the intrauterine insemination  
11  
12 (IUI) cycles: a randomized double blind, Placebo Controlled Study. *J Family Reprod Health* 2014;8: 149.  
13  
14 (13) Hurst SA. Declaration of Helsinki and protection for vulnerable research participants. *JAMA* 2014;311: 1252.  
15  
16 (14) Reindollar RH, Regan MM, Neumann PJ, Levine B-S, Thornton KL, Alper MM, Goldman MB. A  
17  
18 randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard  
19  
20 treatment (FASTT) trial. *Fertil Steril* 2010;94: 888-899.  
21  
22 (15) Karadag B, Dilbaz B, Karcaaltincaba D, Sahin EG, Ercan F, Karasu Y, Tonyali NV. The effect of luteal-phase  
23  
24 support with vaginal progesterone on pregnancy rates in gonadotropin and clomiphene citrate/intra-uterine  
25  
26 insemination cycles in unexplained infertility: A prospective randomised study. *J Obstet Gynaecol* 2016;36:  
27  
28 794-799.  
29  
30 (16) Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson P, Christman GM, Ager J, Huang H,  
31  
32 Hansen KR. Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility. *N Engl J Med* 2015;373:  
33  
34 1230-1240.  
35  
36 (17) Dankert T, Kremer J, Cohlen B, Hamilton C, Pasker-de Jong P, Straatman H, van Dop P. A randomized  
37  
38 clinical trial of clomiphene citrate versus low dose recombinant FSH for ovarian hyperstimulation in  
39  
40 intrauterine insemination cycles for unexplained and male subfertility. *Hum Reprod* 2007;22: 792-797.  
41  
42 (18) Abdelazim IA, Makhlof HH. Sequential clomiphene citrate/hMG versus hMG for ovulation induction in  
43  
44 clomiphene citrate-resistant women. *Arch Gynecol Obstet* 2013;287: 591-597.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Table and Figure Legends**

**Table 1:** Etiology of Infertility for Group A (CC) and Group B (CC+GN or GN only)


**Table 2:** Primary and Secondary Outcomes Obtained for Group A (CC) and Group B (CC+GN /GN only)

**Table 3:** Primary and Secondary Outcomes Obtained for Group B1 (CC+GN) and Group B2 (GN only)

**Figure 1:** Patient Groups as per the Treatments Given in the Present Study


**Figure 2:** Illustration of the Ovarian Stimulation Protocol Standardized During the Present Study

**Figure 1: Patient Groups as per the Treatments Given in the Present Study**



**CC: Clomiphene citrate; GN: Gonadotropins; N: total number of patients in a particular group**

**Figure 2: Illustration of the Ovarian Stimulation Protocol Standardized During the Present Study**



\*Administer hCG (10000 IU) when the endometrial thickness reaches  $\geq 7$  mm and follicle diameter reaches  $\geq 18$  mm.

CC- Clomiphene citrate; hMG: Human Menopausal Gonadotropin; FSH: Follicle Stimulation Hormone; IU: International Units; TVS: Transvaginal Ultrasonography; hCG: Human Chorionic Gonadotropin; IUI: Intrauterine Insemination; IM: Intramuscular.

**Table 1: Etiology of Infertility for Group A (CC) and Group B (CC+GN or GN only)**

<b>Etiologies</b>	<b>CC (n = 115)</b>	<b>CC+GN or GN only (n = 886)</b>
<b>Endometriosis (n = 56)</b>	6 (0.05%)	50 (0.06%)
<b>Male factor (n = 233)</b>	36 (0.31%)	197 (0.22%)
<b>Multifactorial (n = 68)</b>	11 (0.09%)	57 (0.06%)
<b>Ovulatory dysfunction (n = 242)</b>	22 (0.19%)	220 (0.25%)
<b>Unexplained infertility (n = 402)</b>	40 (0.35%)	362 (0.41%)

*p*-value: 0.1161

**Table 2: Primary and Secondary Outcomes Obtained for Group A (CC) and Group B (CC+GN /GN only)**

<b>Outcome Rates (%)</b>	<b>Group A (N= 115)</b>	<b>Group B (N= 886)</b>	<b><i>p</i> value</b>
<b>Primary Outcome</b>	9/115 (7.82%)	129/886 (14.55%)	0.05
Clinical Pregnancy			
<b>Secondary Outcome (Mean ± SD)</b>			
Multiple Pregnancy	0	17/129 (13.17%) <sup>^</sup>	
Miscarriage Rate	1/9 (14.29 %)	7/129 (5.43%)	0.94
Follicle number	1.54 ± 0.69	1.90 ± 1.04	0.0003
Endometrial thickness (mm)	8.56 ± 1.33	8.39 ± 1.29	0.1784

<sup>\*</sup>Group 2A and Group 2B are subgroups of Group B<sup>^</sup> non-evaluable *p*-value.



**Table 3: Primary and Secondary Outcomes Obtained for Group B1 (CC+GN) and Group B2 (GN only)**

<b>Outcome Rates (%)</b>	<b>Group B1 (N= 699)</b>	<b>Group B2 (N= 187)</b>	<b><i>p</i> value</b>
Primary Outcome Clinical Pregnancy	101/699 (14.44%)	28/187 (14.97%)	0.85
<b>Secondary Outcome (Mean ± SD)</b>			
Multiple Pregnancy	11/101 (10.89%)	6/28 (21.42%)	0.14
Miscarriage	6/129 (0.047%)	1/129 (0.008%)	
Follicle number	1.92 ± 0.99	1.65 ± 0.92	0.0008
Endometrial thickness (mm)	8.32 ± 1.27	8.69 ± 1.24	0.0004

CC+GN: 699 and GN only: 187

THE JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA  
Copyright/Authorship/Disclosure Form



MANUSCRIPT ID NUMBER \_\_\_\_\_

FINANCIAL DISCLOSURE/CONFLICT OF INTEREST

I certify that any financial interests such as employment, stock ownership, honoraria, paid expert testimony, as well as any personal relationships, academic competition, and intellectual passion which may inappropriately influence my actions, have been included within my manuscript. If none exist, the statement "Conflict of Interest: None" has been also been included.

All funding sources supporting the work and all institutional or corporate affiliations of mine are acknowledged in a footnote.

I have had full access to all the data in the study (if applicable) and thereby accept full responsibility for the integrity of the data and the accuracy of the data analysis.

By checking the box next to my signature I assert that there are no conflicts of interest (both personal and institutional) regarding specific financial interests that are relevant to the work conducted or reported in this manuscript.

*Manish Banker*  
Author's signature

Manish Banker

Printed name and date

*Appatel*  
Author's signature

Azadeh Patel

Printed name and date

*Ashwini*  
Author's signature

Ashwini Deshmukh

Printed name and date

*Sandeep Shah*  
Author's signature

Sandeep Shah

Printed name and date

\_\_\_\_\_  
Author's signature

Printed name and date

\_\_\_\_\_  
Author's signature

Printed name and date

\_\_\_\_\_  
Author's signature

Printed name and date

\_\_\_\_\_  
Author's signature

Printed name and date

Completed forms can be scanned and included as a pdf file during the online submission process as a supplemental file not for review.